Scott M. Lassman is scheduled to speak about New, Emerging, and Continually Interesting Issues at the Food and Drug Law Institute's Introduction to Biologics and Biosimilars Law and Regulation conference on April 1, 2020.
Scott M. Lassman participated in a panel discussion entitled Biosimilars at the Bar at AAM's GRx+Biosims Conference on November 4, 2019. The panel discussed recent legal developments affecting biosimilars, including interchangeability, labeling carve-outs, enhancements to the Purple Book and regulatory pathways for approval of "biobetters."
Scott M. Lassman is scheduled to speak about New, Emerging, and Continually Interesting Issues at the Food and Drug Law Institute's Introduction to Biologics and Biosimilars Law and Regulation on October 2, 2019 in Washington, D.C.
Scott M. Lassman recently was recognized by The Best Lawyers in America as one of the leading lawyers in America in the categories of FDA Law and Administrative/Regulatory Law.
Best Lawyers' recognitions are based purely on the feedback received from lawyers already highlighted in the publication.
Lassman Law+Policy was privileged to represent Braeburn, Inc. (with co-counsel Goodwin) in securing this U.S. District Court ruling overturning an FDA decision on 3-year exclusivity as unreasonable and arbitrary and capricious. The decision, issued on July 22, 2019, orders FDA to reconsider "with deliberate speed" Braeburn's application for approval of an innovative new injectable treatment for opioid use disorder. Read all about it here.
Lassman Law+Policy recently was honored by LMG Life Sciences by being placed on its "Shortlist" of Regulatory Firms to Watch in 2019. Lassman Law+Policy is the only boutique firm specializing in FDA regulatory law to be recognized in that category. Congratulations to the other nominees: Akin Gump, Debevoise & Plimpton, and Mayer Brown!
LMG Life Sciences evaluates attorneys on the basis of case evidence, peer feedback and client feedback.